Evaluate the Toxicological Risk of Targeting Prolyl-Trna Synthetase, PRS In The Treatment of Malaria.

This presentation discusses work was carried out with MMV the not-for-profit Medicines for Malaria Venture. followed by a summary of the research done around the physiological role of the PRS target.

Speaker: Dr Jane Barber

This talk was presented at Society of Toxicology 2021

This presentation discusses work was carried out with MMV the not-for-profit Medicines for Malaria Venture. Discussion of the malaria the disease will be followed by a summary of the research done around the physiological role of the PRS target and the possible consequences of inhibition of PRS in the human host. The importance of thinking about safety early in the drug discovery programme and considering target, mechanistic and compound related safety will be highlighted.